Bionorica continues to grow with new record turnover
Contrary to trends in this field, the company Bionorica SE is growing. Whilst many pharmaceutical companies of late have been enduring losses, this company is rushing from one success in turnover to the next. Although the so-called OTC-market decreased by 1.5% in the last year, and the segment for phytopharmaceuticals decreased by even 3.3%, Bionorica increased overproportionally by 5.7% plus in 2010 (Source: Insight Health, Pharmacy Sales to Manufacturer Delivery Prices). In doing so Bionorica also significantly surpassed development in the total German pharmacy market (3.7% plus, same source). In total the net turnover of the research and development Bionorica Group in 2010 rose to 149 million €, a plus of 6.2% compared to last year.
Bionorica supplies almost all German pharmacies with compounds in the fields of respiratory medicine, immune system medicine, gynaecology, urology and pain medicine. In contrast to the announcement of reduction of work places in the pharmaceutical industry, Bionorica employed in Germany alone in the last year 6.3% more employees, the number of employees thereby rising worldwide to 950. The company cooperates worldwide with almost 500 universities and clinics to demonstrate the efficacy, quality and minimal side effect profile of plant-based medicines with internationally recognised pharmacological and clinical studies.
For more information see: